ACYCLOVIR SODIUM

Post-LOE

acyclovir sodium

Pfizer

ANDAINJECTIONINJECTABLE

Approved

Apr 1997

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ACYCLOVIR SODIUM (acyclovir sodium) by Pfizer is clinical pharmacology pharmacokinetics the pharmacokinetics of acyclovir after intravenous administration have been evaluated in adult patients with normal renal function during phase 1/2 studies after single doses ranging from 0. Approved for initial, recurrent mucosal, cutaneous herpes simplex (hsv-1 and 5 more indications. First approved in 1997.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Pharmacokinetics The pharmacokinetics of acyclovir after intravenous administration have been evaluated in adult patients with normal renal function during Phase 1/2 studies after single doses ranging from 0.5 to 15 mg/kg and after multiple doses ranging from 2.5 to 15 mg/kg…

Worked on ACYCLOVIR SODIUM at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

ACYCLOVIR SODIUM

Mechanism of Action

Indications (8)